NanoLogix, Inc. (PINK SHEETS: NNLX) announces its new Quick-Test product line for detection and identification of aerobic live-cell bacteria. With the NanoLogix Quick-Tests, the research community will be able to obtain high-sensitivity analysis results in reduced time with lower costs than traditional technologies.
The new NanoLogix Quick Test product line complements the Company’s existing BNP and BNF membrane and filtration technologies with a projected market of medical laboratories, food and beverage producers, pharmaceutical, university and other institutional users.
NanoLogix Quick-Test kit
The NanoLogix Quick-Tests detect and identify a multitude of live-cell bacteria, such as E.coli, Salmonella, and Listeria, with the additional capability of rapid identification of yeasts. These results can be obtained in as little as a quarter of the time of conventional methods, in concentrations potentially as small as a single cell.
Dr. Sergey Gazenko, developer of BNC, BNP, and BNF technologies stated, “We’ve taken our current, peer-reviewed technology and developed the Quick-Test technology to assist in reducing the time required in sample analysis and subsequent diagnosis.”
“With infectious diseases being the second leading cause of death worldwide, the demand for fast, inexpensive and simple testing methods that do not require specialized equipment or complex training is growing. To assist in satisfying that demand, NanoLogix's Quick-Tests were developed to provide the ability to obtain rapid analysis results without large capital expenditures and increased burdens on existing staff,” said Bret Barnhizer, NanoLogix CEO.
Each Quick-Test kit is designed to provide results for fifty individual tests of the targeted bacteria and each test kit is identified by the name of that specific bacteria, e.g., E.coli Quick-Test, Salmonella Quick-Test, etc. NanoLogix currently has Quick Tests available for E.coli, Salmonella, and Listeria with additional bacteria Quick-Tests available upon request.